The clinical need for clustered AChR cell-based assay testing of seronegative MG.

Journal Article (Journal Article)

Trial eligibility in myasthenia gravis (MG) remains largely dependent on a positive autoantibody serostatus. This significantly hinders seronegative MG (SNMG) patients from receiving potentially beneficial new treatments. In a subset of SNMG patients, acetylcholine receptor (AChR) autoantibodies are detectable by a clustered AChR cell-based assay (CBA). Of 99 SNMG patients from two academic U.S. centers, 18 (18.2%) tested positive by this assay. Autoantibody positivity was further validated in 17/18 patients. In a complementary experiment, circulating AChR-specific B cells were identified in a CBA-positive SNMG patient. These findings corroborate the clinical need for clustered AChR CBA testing when evaluating SNMG patients.

Full Text

Duke Authors

Cited Authors

  • Masi, G; Li, Y; Karatz, T; Pham, MC; Oxendine, SR; Nowak, RJ; Guptill, JT; O'Connor, KC

Published Date

  • June 15, 2022

Published In

Volume / Issue

  • 367 /

Start / End Page

  • 577850 -

PubMed ID

  • 35366559

Pubmed Central ID

  • PMC9106915

Electronic International Standard Serial Number (EISSN)

  • 1872-8421

Digital Object Identifier (DOI)

  • 10.1016/j.jneuroim.2022.577850

Language

  • eng

Conference Location

  • Netherlands